Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses

Paul V Licciardi; Anne Balloch; Fiona M Russell; Robert L Burton; Jisheng Lin; Moon H Nahm; Edward K Mulholland; Mimi LK Tang

Journal article

Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses

Paul V Licciardi, Anne Balloch, Fiona M Russell, Robert L Burton, Jisheng Lin, Moon H Nahm, Edward K Mulholland, Mimi LK Tang

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | MOSBY-ELSEVIER | Published : 2012

DOI: 10.1016/j.jaci.2011.11.043

Abstract

BACKGROUND: Infections with Streptococcus pneumoniae (pneumococcus) are a cause of significant child mortality. Pneumococcal glycoconjugate vaccines are expensive and provide limited serotype coverage. The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might provide wider serotype coverage but is reported to be weakly immunogenic in children less than 2 years of age. We have previously reported that Pneumovax administered to healthy 12-month-old Fijian infants elicits significant serotype-specific IgG responses. However, the functional capacity of these responses in 12-month-old infants is not known. OBJECTIVE: We sought to assess the functional, serotype-specific immune response ..

View full abstract

University of Melbourne Researchers

Kim Mulholland Author Paediatrics Royal Children's Hospital

Fiona Russell Author Paediatrics Royal Children's Hospital

Mimi Tang Author Paediatrics Royal Children's Hospital

Paul Licciardi Author Paediatrics Royal Children's Hospital

Related Projects (2)

A study to investigate alternative regimens for pneumococcal vaccination of infants in a developing country

Streptococcus pneumoniae (Pnc) is the leading vaccine preventable cause of serious infection in infants. The current Pnc conjugate vaccine i..

Appropriate pneumococcal vaccination in infants in Fiji

DESCRIPTION (provided by applicant): The Fiji Pneumococcal Project that has been funded by NIH has been designed to provide all the informat..

Grants

Awarded by National Institute of Allergy and Infectious Diseases (NIAID)

Awarded by Australian National Health and Medical Research Council (NHMRC)

Awarded by National Institutes of Health

Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Funding Acknowledgements

Supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID; 2 U01 AI052337-05), the Australian National Health and Medical Research Council (NHMRC grant no. 251648), and the Victorian Government's Operational Infrastructure Support Program. Pneumovax was kindly donated by CSL Biotherapies, Australia. M.H.N. is supported by National Institutes of Health contract AI-30021.M. H. Nahm has consultant arrangements with Merck and receives research support from the National Institutes of Health. E. K. Mulholland receives research support from the National Institutes of Health and the Gates Foundation. M. L. K. Tang is a member of the Asia Pacific Medical Advisory Board for Nestle Nutrition Institute, is a member of the Medical Advisory Board for Wyeth, is a speaker for Danone, and receives research support from the Nestle Research Center. The rest of the authors declare that they have no relevant conflicts of interest.